These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2885637)

  • 1. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
    Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation.
    Lancet; 1985 Apr; 1(8433):836-40. PubMed ID: 2858709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
    Fisher B; Costantino J; Redmond C; Poisson R; Bowman D; Couture J; Dimitrov NV; Wolmark N; Wickerham DL; Fisher ER
    N Engl J Med; 1989 Feb; 320(8):479-84. PubMed ID: 2644532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group.
    Stewart HJ
    J Natl Cancer Inst Monogr; 1992; (11):117-20. PubMed ID: 1320920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation.
    Lancet; 1983 Feb; 1(8319):257-61. PubMed ID: 6130291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo.
    Cummings FJ; Gray R; Davis TE; Tormey DC; Harris JE; Falkson G; Arseneau J
    Ann Intern Med; 1985 Sep; 103(3):324-9. PubMed ID: 3896085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
    Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
    Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial.
    Delozier T; Julien JP; Juret P; Veyret C; Couëtte JE; Graic Y; Ollivier JM; de Ranieri E
    Breast Cancer Res Treat; 1986; 7(2):105-9. PubMed ID: 3521767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endocrine therapy for operable breast cancer.
    Stewart HJ
    Bull Cancer; 1991; 78(4):379-84. PubMed ID: 1859906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
    Forrest AP; Stewart HJ; Everington D; Prescott RJ; McArdle CS; Harnett AN; Smith DC; George WD
    Lancet; 1996 Sep; 348(9029):708-13. PubMed ID: 8806289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.